

	Sagent Pharmaceuticals		
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection	
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025

Section 1 - Identification

- (a) **Product Identifier:** Zoledronic Acid Injection
- (b) **NDC:** 25021-801-66, 25021-826-67, 25021-826-82, 25021-826-87
- Common/Trade Name:** Zometa®
- Chemical Name:** (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate
- Chemical Family:** Bisphosphonate
- (c) **Product Use:** Hypercalcaemia of Malignancy, tumor induced hypercalcemia
- Product Type:** Regulated Prescription Drug
- Container Information:** Vial and Bag
- (d) **Distributor:** Sagent Pharmaceuticals, 1515 E Woodfield Road Suite 1100, Schaumburg, IL 60173
- (e) **Emergency Telephone:** 866-625-1618

Section 2 - Hazards Identification

- (a) **Classification:** **GHS Classification:**
Toxic to Reproduction, Category 2
- NFPA Rating**
- | | |
|-------------------|---|
| Health Hazard | 1 |
| Fire Hazard | 0 |
| Reactivity Hazard | 0 |

sagent	Sagent Pharmaceuticals		
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection	
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025

(b) Signal Word, Hazard statement(s), Symbol(s), and/or Precautionary statement(s):	(c) Description of Hazards:
<u>Signal Word:</u> <u>Symbol</u>	- WARNING 
H361fd	<u>GHS Hazard Statements:</u> - Suspected of damaging fertility. Suspected of damaging the unborn child.
P201 P202 P281 P308 + P313 P501	<u>GHS Precautionary Statements:</u> - Obtain special instructions before use. - Do not handle until all safety precautions have been read and understood - Use personal protective equipment as required - IF exposed or concerned: Get medical attention/advice - Dispose of contents/container in accordance with local/regional/national/international regulations

(d) Unknown Acute Toxicity: N/A

	Sagent Pharmaceuticals			
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection		
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025	

Section 3 – Composition / Information on Ingredients

(a) Chemical Name	(b) Common Name / Synonym	% Composition or other measure		(c) CAS No.	(d) Impurities / Stabilizing Additives
		4 mg / 5mL vial	4 mg / 100mL bag		
(1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate	Zoledronic Acid	0.08% (w/v)	0.004% (w/v)	118072-93-8	N/A
Sodium Chloride	Sodium Chloride	--	0.89% (w/v)	7647-14-5	N/A
(2R,3R,4R,5R)-Hexan-1,2,3,4,5,6-hexol	Mannitol	4.19% (w/v)	0.22% (w/v)	69-65-8	N/A
Sodium Citrate	Sodium Citrate	0.46% (w/v)	pH Adj.	6132-04-3	N/A
Water	Water for Injection	95.27% (w/v)	98.89% (w/v)	7732-18-5	N/A

Section 4 - First Aid Measures

Eye Exposure:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Exposure:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Injection:	See patient package insert in shipping carton for complete information.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Notes to Physician:	See patient package insert in shipping carton for complete information.

Previous Document No SDS061	Confidential - For Use Only By Affiliates of Sagent Pharmaceuticals	Page Page 3 of 10
---------------------------------------	--	-----------------------------

	Sagent Pharmaceuticals			
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection		
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025	

Section 5 –Fire-fighting Measures

- (a) **Extinguishing Media** Use carbon dioxide, dry chemical, or water spray
- (b) **Hazardous Combustion Products:** Fine particles (such as dust and mists) may fuel fires/explosions.
- (c) **Special Protective Equipment / Precautions:** During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Section 6 - Accidental Release Measures

Spill: Contain the source of the spill if it is safe to do so. Collect spilled material in a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly. Place waste in an appropriately labeled, sealed container for disposal.

Large spills – non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

Release to Air: Care should be taken to avoid environmental release.

Release to Water: Refer to local water authority. Drain disposal is not recommended; refer to local, state, and federal disposal guidelines.

Section 7 - Handling and Storage

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. Use appropriate personal protective equipment (PPE) while handling (see section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided.

Storage Conditions: Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). [See Controlled Room Temperature]. Follow instructions provided in packaging.

	Sagent Pharmaceuticals		
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection	
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025

Section 8 - Exposure Controls / Personal Protection

(a) Exposure Limits

Compound	Issuer	Type	Exposure Limit
Zoledronic Acid	OSHA	PEL	NE
	ACGIH	TLV	NE
	----	STEL	NE
Mannitol	OSHA	PEL	NE
	ACGIH	TLV	NE
	----	STEL	NE
Sodium Citrate	OSHA	PEL	NE
	ACGIH	TLV	NE
	----	STEL	NE

(b) Engineering Controls

Ventilation: Engineering controls should be used as a primary means of control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits of $>1\mu\text{g}/\text{m}^3$ to $<10\mu\text{g}/\text{m}^3$

(c) Individual Protection Measures

Respiratory Protection:	If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.
Eye Protection:	Wear safety glasses or goggles if eye contact is possible.
Skin Protection:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Other Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Additional Exposure Precautions:	Not applicable

	Sagent Pharmaceuticals		
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection	
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025

Section 9 - Physical and Chemical Properties

(a)	Appearance	Clear, colorless solution
(b)	Odor	Not Available
(c)	Odor Threshold	Not Available
(d)	pH	6.0-7.0
(e)	Melting Point:	Not Available
(f)	Initial Boiling Point:	Not Available
(g)	Flash Point	Not Available
(h)	Evaporation Rate:	Not Available
(i)	Flammability	Not Available
(j)	Upper Lower Flammability or Explosion Limits	Not Available
(k)	Vapor Pressure:	Not Available
(l)	Vapor Density:	Not Available
(m)	Relative Density	Not Available
(n)	Solubility(ies)	Highly Soluble in water
(o)	Partition Coefficient: n-octanol/water	Not Available
(p)	Auto-ignition Temperature	Not Available
(q)	Decomposition Temperature	Not Available
(r)	Viscosity	Not Available

Section 10 - Stability and Reactivity

(a)	Reactivity	Not Available
(b)	Chemical Stability	Stable under normal conditions of use.
(c)	Possibility of Hazardous Reactions	Hazardous polymerization will not occur
(d)	Conditions to Avoid	Protect from light and temperatures exceeding 86 °F (30 °C).
(e)	Incompatible Materials	As a precautionary measure, keep away from strong oxidizers.
(f)	Hazardous Decomposition Products	Carbon monoxide, carbon dioxide, formed under fire conditions

	Sagent Pharmaceuticals			
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection		
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025	

Section 11 - Toxicological Information

(a)	Likely Routes of Exposure	Skin and eye contact, ingestion, inhalation
(b)	Symptoms related to the physical, chemical and toxicological characteristics	Common adverse effects include nausea, vomiting, gastrointestinal irritation, fatigue, decreased red blood cell count (anemia), constipation, fever, shortness of breath (dyspnea) and bone pain.
(c)	Delayed and immediate effects and also chronic effects from short and long term exposure	May damage fertility or unborn child.

(d) Acute Toxicity

Component	Type	Route	Species	Dosage
Zoledronic Acid	Minimum Lethal Dose	Intravenous	Mouse	>10 mg/Kg
Zoledronic Acid	Minimum Lethal Dose	Intravenous	Rat	>0.6 mg/Kg
Mannitol	LD ₅₀	Oral	Rat	13500 mg/kg
Mannitol	LD ₅₀	Oral	Mouse	22.00 g/kg

(e) Hazardous Chemical Listings

NTP: Not Listed IARC: Not Listed OSHA: Listed

NIOSH: Listed Group 3: Non antineoplastic drugs that primarily have adverse reproductive effects

Section 12 - Ecological Information

(a)	Ecotoxicity	Data is for drug substance and not finished product. <u><i>Daphnia Magna</i> (water flea) Toxicity</u> EC50 after 48 hrs: > 18 mg/L <u><i>Algae (selenastrum capricornutum)</i> Toxicity</u> EbC50 (72 hrs): 5.1 mg/L ErC50 (72 hrs): 15 mg/L NoEC (72 hrs): 2.2 mg/L
(a)	Ecotoxicity	<u>Bacterial Respiration (Activated Sludge) Inhibition:</u>

Previous Document No SDS061	Confidential - For Use Only By Affiliates of Sagent Pharmaceuticals	Page Page 7 of 10
---------------------------------------	--	-----------------------------

	Sagent Pharmaceuticals			
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection		
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025	

		EC50: 100 mg/L
(b)	Persistence and degradability	Data is for drug substance and not finished product. Degradation is 1-3% over a duration of 28 days
(c)	Bioaccumulative potential	No applicable ecological information found.
(d)	Mobility in soil	No applicable ecological information found.
(e)	Other Adverse Effects	No applicable ecological information found.

Section 13 - Disposal Considerations

Waste Disposal: Dispose of any cleanup materials and waste residue according to all applicable laws and regulations.

Section 14 - Transport Information

DOT: Not regulated
ICAO/IATA: Not regulated
IMDG: Not regulated

Section 15 - Regulatory Information

Below is selected regulatory information chosen primarily for possible Sagent usage. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your country/state.

U.S. Regulations:

TSCA - No
CERCLA - Not on this list
SARA 302 - Not on this list
SARA 311/312 – Acute health effects, chronic health effects
SARA 313 – Not listed
OSHA Substance Specific - No
RCRA – Not listed

Section 16 - Other Information

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for

Previous Document No SDS061	Confidential - For Use Only By Affiliates of Sagent Pharmaceuticals	Page Page 8 of 10
--	--	-----------------------------

	Sagent Pharmaceuticals			
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection		
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025	

consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:

Sagent Pharmaceuticals,
1515 E Woodfield Road Suite 1100
Schaumburg, IL 60173
847-908-1600

Glossary: This glossary contains definitions of general terms used in SDSs. Not all of these Glossary Terms will apply to this SDS.

ACGIH	American Conference of Governmental Industrial Hygienists
AICS	Australian Inventory of Chemical Substances
AIHA	American Industrial Hygiene Association
ANSI	American National Standards Institute
CAS Number	Chemical Abstract Service Registry Number
CERCLA	Comprehensive Environmental Response Compensation and Liability Act (of 1980)
CHAN	Chemical Hazard Alert Notice
CHEMTREC	Chemical Transportation Emergency Center
DOT	Department of Transportation
DSL	Domestic Substances List
ECHA	European Chemicals Agency
EINECS	European Inventory of Existing Commercial Chemical Substances
ELINCS	European List of Notified Chemical Substances
EPA	Environmental Protection Agency
GHS	Globally Harmonized System of Classification and Labelling of Chemicals
HEPA	High Efficiency Particulate Air (Filter)
HMIS	Hazardous Materials Identification System
IARC	International Agency for Research on Cancer
ICAO/IATA	International Civil Aviation Organization/International Air Transport Association
IMDG	International Maritime Dangerous Goods
IMO	International Maritime Organization
KOW	Octanol/Water Partition Coefficient
LEL	Lower Explosive Limit
MSDS	Material Safety Data Sheet
MSHA	Mine Safety and Health Administration
NA	Not Applicable, except in Section 14 where NA = North America
NE	Not Established
NADA	New Animal Drug Application
NAIF	No Applicable Information Found
NCI	National Cancer Institute
NDSL	Non-Domestic Substances List
NFPA	National Fire Protection Association

Previous Document No SDS061	Confidential - For Use Only By Affiliates of Sagent Pharmaceuticals	Page Page 9 of 10
--	--	-----------------------------

	Sagent Pharmaceuticals		
	Document Type Safety Data Sheet (SDS)	Document Title Zoledronic Acid Injection	
	Document No. MSDS-0059	Version 10.0	Effective Date 26 Jul 2025

NIOSH	National Institute for Occupational Safety and Health
NPDES	National Pollutant Discharge Elimination System
NOS	Not Otherwise Specified
NTP	National Toxicology Program
OSHA	Occupational Safety and Health Administration
OEL	Occupational Exposure Limit
PEL	Permissible Exposure Limit (OSHA)
RCRA	Resource Conservation and Recovery Act
RQ	Reportable Quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SDS	Safety Data Sheet
STEL	Short Term Exposure Limit
TLV	Threshold Limit Value (ACGIH)
TPQ	Threshold Planning Quantity
TSCA	Toxic Substances Control Act
TWA	Time Weighted Average/8 Hours Unless Otherwise Noted
UEL	Upper Explosive Limit
UN	United Nations
USP	United States Pharmacopeia
WEEL	Workplace Environmental Exposure Level (AIHA)
WHMIS	Workplace Hazardous Materials Information System